AI Terminal

MODULE: AI_ANALYST
Interactive Q&A, Risk Assessment, Summarization
MODULE: DATA_EXTRACT
Excel Export, XBRL Parsing, Table Digitization
MODULE: PEER_COMP
Sector Benchmarking, Sentiment Analysis
SYSTEM ACCESS LOCKED
Authenticate / Register Log In

Pixium Vision

Pre-Annual General Meeting Information May 10, 2023

1599_agm-r_2023-05-10_04210c2b-a56a-4006-8ba4-cf12d82bd73a.pdf

Pre-Annual General Meeting Information

Open in Viewer

Opens in native device viewer

Pixium Vision convenes its Annual Meeting of Shareholders on June 13, 2023

Paris, France, May 10, 2023 – 07:00 p.m. CET – Pixium Vision SA (Euronext Growth Paris - FR0011950641), a bioelectronics company that develops innovative bionic vision systems to enable patients who have lost their sight to live more independent lives, announces that it will hold its annual meeting of shareholders at 14:00 CET on June 13, 2023 at Pixium Vision's headquarter office. The meeting will take place in person.

The notice of the meeting published in the BALO (Bulletin des Annonces Légales Obligatoires) n°55 on May 8 2023 is available on the Company's website (www.pixium-vision.com) under «Shareholders' General Meeting».

Information and documents relating to the Annual Meeting will be available on the Company's website as from the convening of the shareholders in accordance with applicable laws and regulations.

About Pixium Vision

Pixium Vision is creating a world of bionic vision for those who have lost their sight, enabling them to regain visual perception and greater autonomy. Pixium Vision's bionic vision systems are associated with a surgical intervention and a rehabilitation period. Prima System sub-retinal miniature photovoltaic wireless implant is in clinical testing for patients who have lost their sight due to outer retinal degeneration, initially for atrophic dry age-related macular degeneration (dry AMD). Pixium Vision collaborates closely with academic and research partners, including some of the most prestigious vision research institutions in the world, such as Stanford University in California, Institut de la Vision in Paris, Moorfields Eye Hospital in London, Institute of Ocular Microsurgery (IMO) in Barcelona, University hospital in Bonn, and UPMC in Pittsburgh, PA. The Company is EN ISO 13485 certified and qualifies as "Entreprise Innovante" by Bpifrance.

For more information: http://www.pixium-vision.com/fr Follow us on @PixiumVision; www.facebook.com/pixiumvision www.linkedin.com/company/pixium-vision

Pixium Vision is listed on Euronext Growth Paris. Euronext ticker: ALPIX - ISIN: FR0011950641

Pixium Vision shares are eligible for the French tax incentivized PEA-PME and FCPI investment vehicles.

Pixium Vision is included in the Euronext GROWTH ALLSHARE index

Contacts

Investor Relations Pixium Vision Offer Nonhoff [email protected] Media Relations Rose Piquante Consulting Sophie Baumont [email protected] +33 6 27 74 74 49

Talk to a Data Expert

Have a question? We'll get back to you promptly.